



Figure S2 Labbe plot for heterogeneity evaluation of tofacitinib versus placebo for efficacy (A) and safety indicators (B). **A:** Heterogeneity analysis of tofacitinib studies at different dosages and different dosing time for PASI 75, PGA 0/1, and PASI 90. **B:** Heterogeneity analysis of tofacitinib studies at different dosages and different dosing time for Nasopharyngitis, Hypercholesterolemia, Headache, and URTI. The diagonal ($x = y$) oblique line represents the risk ratio (RR) equal to one. The dashed line indicates the RR of the studies. The size of each circle is proportional to the sample size of each study.